Should you forget Eli Lilly and buy this magnificent biotech instead? Let's find out.

In a report released today, Joon Lee from Truist Financial assigned a Buy rating to Voyager Therapeutics (VYGR – Research Report). The ...

On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $60.6 which represents a decrease of $-2.37 or -3.76% from the prior close of $62.97. The stock opened at $62.46 and ...

Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral ...

So far this year, Eli Lilly (NYSE: LLY) has been on an absolute tear and is swiftly becoming the world's most prolific ...

In recent trading, Viking Therapeutics Inc (VKTX) stock price has shown some volatility, fluctuating -6.04% over the last five trades and 9.66% over the past 30 trades. This represents a notable shift ...

A small player like Viking may also win by attracting a partner or even a company that will offer to acquire the biotech.

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity, to ...

Viking Therapeutics reported updated, early-stage study results on its oral obesity drug candidate. Vertex Pharmaceuticals ...

Conference call with CEO Dr. Lian and CFO Zante to be held on November 5 at 11:30 am hosted by JPMorgan. Webcast Link Published first on ...

Viking Therapeutics reported clinical trial data on Sunday, which excited some investors. Despite signs that Viking's ...